Dose.com

What Dose.com does

Dose Limited (trading as Dose.com) is a UK-based, seed-stage medical device company developing the Dose Patch, described as an intelligent, programmable transdermal drug delivery system. Founded in 2024 and headquartered at 71-75 Shelton Street, Covent Garden, London, with stated origin in Edinburgh, the company combines a multi-reservoir patch architecture with microneedle or transdermal absorption to deliver timed, controlled dosing without patient intervention. Built-in sensors monitor delivery, adherence, and biometric metrics, and data is synced to a patient-facing app and a physician dashboard for live treatment oversight. No granted patents or trademarks are disclosed; IP filings are in progress around custom payload delivery hardware and programmable release profiles.

The company's platform is positioned horizontally across at least seven therapeutic use cases, with stated primary focus on subcutaneous immunotherapy for allergy desensitisation, alongside GLP-1 drugs (including Ozempic, Wegovy, Mounjaro), ADHD, clinical trials, pain management, cardiovascular, and anti-nausea indications. Dose.com generates (or plans to generate) revenue through four streams: B2B pharma partnerships under licensing/royalty arrangements, subscription-based drug-trial platform services, hardware device sales to hospitals and clinics, and recurring subscription/data services for adherence tracking and analytics. The go-to-market motion is enterprise field sales targeting pharma companies and healthcare institutions; no public pricing or named customers are disclosed.

Dose.com is led by Founder & CEO Luke Heron (prior co-founder of TestCard, integrated into NHS Trusts and licensed by Roche; ex-Merrill Lynch), Chairman Paul Cooper (former partner at PwC/KPMG/Grant Thornton; ex-COO at Lion Capital), Finance Director Nick Ydlibi (ex-EY; 20+ years at Boots Company), and a board of advisors drawn from Amazon product leadership, IP law (Withers Tech), NHS procurement (Guy's and St Thomas'), and clinical practice. A four-person engineering team operates the development function with experience in ISO 9001 and ISO 13485 regulated environments. The company is currently raising a £1 million seed round at a £4.2 million pre-money valuation and is pre-revenue.

Name

Dose.com

Legal name

Dose Limited

Website

https://dose.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Dose.com develops the Dose Patch, an intelligent, programmable transdermal drug delivery system with multi-reservoir dosing, embedded sensors, and a connected patient/clinician platform. The UK-based seed-stage company targets pharmaceutical companies, clinical trial sponsors, and hospitals across multiple therapeutic areas including allergy, GLP-1, ADHD, and pain.

Ownership category

akta.pro rank

Headquarters

HQ city

Edinburgh

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. B2B Pharma Partnerships: Pharma companies integrate their drugs into Dose's transdermal platform, extending patent life and improving drug efficacy. Revenue generated through licensing/royalty arrangements with pharmaceutical partners.
2. Drug Trials Platform: Remote drug delivery with real-time monitoring for clinical trials. Faster recruitment, lower costs, and better patient compliance. Revenue from pharmaceutical trial sponsors.
3. Direct-to-Healthcare: Hospitals and clinics use Dose for controlled, automated drug delivery, reducing labour costs and improving adherence. One-time device sales with potential recurring component.
4. Subscription & Data Services: Real-time adherence tracking and biometric data provide valuable insights. Subscription fees cover remote monitoring and analytics services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Dose.com develops and sells the Dose Patch, an intelligent, programmable transdermal patch that automates timed drug release through a multi-reservoir system with microneedle-based delivery. The patch includes embedded sensors that monitor drug delivery and adherence in real time and syncs data to a connected patient app and physician dashboard. The platform supports therapeutic applications including allergen desensitisation, GLP-1 delivery, ADHD treatment, pain management, cardiovascular and anti-nausea medications, along with remote clinical trial delivery.

Product overview

Dose.com offers a single unified product — the Dose Patch — which is the world's first intelligent, programmable transdermal patch. The patch automates dosing, provides real-time monitoring, and syncs data to a connected patient app and physician dashboard. The platform supports multiple therapeutic applications including allergy exposure therapy, GLP-1 drugs, ADHD treatment, drug trials, pain management, cardiovascular, and anti-nausea medications, delivered via transdermal or microneedle-based mechanisms.

Differentiator

Problem solved

Functional benefit

Products and services

• Dose Patch The world's first intelligent, programmable transdermal patch that automates medication dosing via a multi-reservoir system and microneedle-based transdermal absorption, with embedded sensors providing real-time monitoring of drug delivery and patch adherence synced to a patient app and physician dashboard. Targeted at pharmaceutical partners, hospitals, clinics, and clinical trial sponsors.
• Drug Trials Platform Remote drug delivery with real-time monitoring service for clinical trial sponsors, enabling faster patient recruitment, lower trial costs, and improved patient compliance by replacing in-clinic dosing with monitored home-based delivery through the Dose Patch and connected platform.

Segments8 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/dosepatch
• LinkedInlinkedin.com/company/105513635

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dose.com